Related references
Note: Only part of the references are listed.The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Marilyn S. Albert et al.
ALZHEIMERS & DEMENTIA (2011)
Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive Impairment
Ozioma C. Okonkwo et al.
ARCHIVES OF NEUROLOGY (2011)
Overcoming Metastatic Melanoma with BRAF Inhibitors
Seunghee Hong et al.
ARCHIVES OF PHARMACAL RESEARCH (2011)
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
BRAF targeted therapy changes the treatment paradigm in melanoma
Antoni Ribas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Been There, Not Done That - Melanoma in the Age of Molecular Therapy
Marc S. Ernstoff
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The molecular basis of the blood brain barrier differentiation and maintenance. Is it still a mystery?
Roberta Paolinelli et al.
PHARMACOLOGICAL RESEARCH (2011)
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
John Q. Trojanowski et al.
ALZHEIMERS & DEMENTIA (2010)
Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans
Paul S. Aisen et al.
ALZHEIMERS & DEMENTIA (2010)
Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease
Madhav Thambisetty et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Rebecca Craig-Schapiro et al.
BIOLOGICAL PSYCHIATRY (2010)
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
Kaisa Samgard et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
MECHANISMS OF DISEASE Alzheimer's Disease
Henry W. Querfurth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects
Leslie M. Shaw et al.
ANNALS OF NEUROLOGY (2009)
AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease
Simon Lovestone et al.
BIOMARKERS IN BRAIN DISEASE (2009)
Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels
Holly D. Soares et al.
BIOMARKERS IN BRAIN DISEASE (2009)
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tero Tapiola et al.
ARCHIVES OF NEUROLOGY (2009)
Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid
Timo Grimmer et al.
BIOLOGICAL PSYCHIATRY (2009)
Rapid Progression from Mild Cognitive Impairment to Alzheimer's Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype
Elin S. Blom et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2009)
Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
A. K. Wallin et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2009)
Use of Alzheimer Disease Biomarkers Potentially Yes for Clinical Trials but Not Yet for Clinical Practice
Ronald C. Petersen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Niklas Mattsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Applicability of a Genetic Signature for Enhanced Iloperidone Efficacy in the Treatment of Schizophrenia
Simona Volpi et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Novel consortium to address shortfall in innovative medicines for psychiatric disorders
Bethan Hughes
NATURE REVIEWS DRUG DISCOVERY (2009)
Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1
Joshua S. Hunt et al.
PHARMACOTHERAPY (2009)
CCR5 as target for HIV-1 gene therapy
Reza Nazari et al.
CURRENT GENE THERAPY (2008)
A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression
Andre Russowsky Brunoni et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2008)
PET imaging of amyloid deposition in patients with mild cognitive impairment
Anton Forsberg et al.
NEUROBIOLOGY OF AGING (2008)
The concept of endophenotypes in psychiatric diseases meeting the expectations?
I. Puls et al.
PHARMACOPSYCHIATRY (2008)
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Sandip Ray et al.
NATURE MEDICINE (2007)
Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2007)
Imaging β-amyloid burden in aging and dementia
C. C. Rowe et al.
NEUROLOGY (2007)
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
Katharina Buerger et al.
BRAIN (2006)
Proteome-based plasma biomarkers for Alzheimer's disease
A. Hye et al.
BRAIN (2006)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson et al.
LANCET NEUROLOGY (2006)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
AM Fagan et al.
ANNALS OF NEUROLOGY (2006)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Correlation of cerebrospinal fluid levels of Tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease
H Hampel et al.
ARCHIVES OF NEUROLOGY (2005)
Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework
AH Fanous et al.
MOLECULAR PSYCHIATRY (2005)
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
WE Klunk et al.
ANNALS OF NEUROLOGY (2004)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
Toward molecular diagnostics of mood disorders in psychiatry
S Avissar et al.
TRENDS IN MOLECULAR MEDICINE (2002)
Prospects for neurology and psychiatry
WM Cowan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
